Mayo Clinic Structural Cardiology Nurse Practitioner! Wife & fur baby mama! Life long learner! Constantly trying to juggle all of the above. Tweets are my own.
Congratulations, Dr. Mohamad Alkhouli! I cannot think of anyone more qualified and deserving!! Grateful to have you as a mentor and colleague! @adnanalkhouli
We’re pleased to announce Dr. Mohamad Alkhouli (@adnanalkhouli) as the next editor-in-chief of #JACCINT. He brings global expertise in interventional cardiology, CV research, and 10+ years of editorial leadership. 👏👏👏
Learn more about him here: https://t.co/knsHdQLAMd
Dear colleagues from around the world, I hope you can join us at this course in Puerto Vallarta. It will be informative and fun!!! Hope to see you there! 😃
FRIDAY: Join @MayoClinic interventional cardiologist @adnanalkhouli and moderator @mandeep_mayo for a free hour-long #webinar on LAA Closure.
Can't join? All registrants will be notified when the recording is available. https://t.co/cIaKscMi8y
We're excited to launch an all-new #Interventional#CME course in 2025! Don't miss this thrilling, interactive new program on complex interventional cases while enjoying a rejuvenating getaway. Get details and register here: https://t.co/3kGHSsISFe @rajivxgulati@adnanalkhouli
Mayo Clinic in Rochester has once again been named the #1 hospital in the world by @Newsweek in their 2024 rankings. Thank you to our exceptional staff who remain committed to our primary value of putting patients’ needs first. https://t.co/i6TGDVbBwu #WorldsBestHospitals
Newsweek ranks @MayoClinicCV & @MayoClinicCVS #1 globally. An extraordinary team, collaborating to tackle complex diagnoses, restoring health & providing comfort, encouragement & hope to all of our patients.
https://t.co/FDJeVPsAb2
https://t.co/wq0VeaLnL1
#CVI2023 always delivers and consistently is #settingthebar higher and higher..see you next year!
Heart Team Symposium
Faculty and discussants
#risingthetide🌊
What a celebration. Celebrating the retirement of Dr. David Holmes. This was an evening to remember for sure. Thank you for inspiring us to be the best versions of ourselves. Your legacy will live on through all of those you have mentored.
Tricuspid regurgitation in 2023: a turning point! S. Pislaru, MD @MayoClinicCV & J. Crestenallo, MD @MayoClinicCVS review the basics, is it bad for you?, risk assessment & interventions in this recent webinar.
https://t.co/uKQA9fCNZE
MITRAL Trial 2 y outcomes. Survival in MViV 93.3%! Mortality higher in ViMAC 39.3% & MViR 50% (for reference 2Y TAVR death PARTNER 1 was 43%). MViV, MViR & ViMAC associated with improved symptoms, QoL & stable THV function.@MayoClinicCV